Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
103 hedge funds and large institutions have $94.2M invested in Insys Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 20 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
12% more capital invested
Capital invested by funds: $84M → $94.2M (+$10.1M)
6% less funds holding
Funds holding: 110 → 103 (-7)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
43% less call options, than puts
Call options by funds: $3.55M | Put options by funds: $6.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$1.53M |
| 2 |
BlackRock
New York
|
+$1.35M |
| 3 |
Millennium Management
New York
|
+$1.19M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.06M |
| 5 |
JG
Jefferies Group
New York
|
+$357K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$3.43M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.47M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$453K |
| 5 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$399K |
INSY Hedge Fund Activity: Q2 2018 in Review
103 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2018, worth a combined $94.2M — up 12% from $84M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of INSY and 14 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 31 added.
The largest buyer was ETF Managers Group, adding an estimated $1.53M. The largest seller was Norges Bank, cutting an estimated $3.43M.
- 103 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2018, down from 110 in Q1 2018.
- Funds reported $94.2M of Insys Therapeutics, Inc. stock for Q2 2018, up 12% quarter-over-quarter.
- 14 funds opened new Insys Therapeutics, Inc. positions in Q2 2018 and 20 closed out, a net change of -6 holders.
- The largest Insys Therapeutics, Inc. buyer in Q2 2018 was ETF Managers Group, an estimated $1.53M added.
- The largest Insys Therapeutics, Inc. seller in Q2 2018 was Norges Bank, an estimated $3.43M sold.
Based on aggregated 13F filings for Q2 2018.